<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biosci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Biosci. Rep</journal-id><journal-id journal-id-type="publisher-id">bsr</journal-id><journal-title-group><journal-title>Bioscience Reports</journal-title></journal-title-group><issn pub-type="ppub">0144-8463</issn><issn pub-type="epub">1573-4935</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31872854</article-id><article-id pub-id-type="pmc">6954369</article-id><article-id pub-id-type="doi">10.1042/BSR20192546</article-id><article-id pub-id-type="publisher-id">BSR20192546</article-id><article-categories><subj-group subj-group-type="heading"><subject>Bioinformatics</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>DNA, Chromosomes &#x00026; Chromosomal Structure</subject></subj-group><subj-group subj-group-type="heading"><subject>Diagnostics &#x00026; Biomarkers</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="AFF1"/></contrib><contrib contrib-type="author"><name><surname>Theobard</surname><given-names>Rutaganda</given-names></name><xref ref-type="aff" rid="AFF1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jianying</given-names></name><xref ref-type="aff" rid="AFF2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0006-4042</contrib-id><name><surname>Dai</surname><given-names>Xiaofeng</given-names></name><email>1281423490@qq.com</email><xref ref-type="aff" rid="AFF3"/><xref ref-type="aff" rid="AFF4"/><xref ref-type="corresp" rid="COR1"/></contrib></contrib-group><aff id="AFF1"><label>1</label>School of Biotechnology, Jiangnan University, Wuxi, China</aff><aff id="AFF2"><label>2</label>Henan Institute of Medical and Pharmaceutical Sciences and Henan Key Laboratory of Tumor Epidemiology, Zhengzhou University, Zhengzhou 450001, China</aff><aff id="AFF3"><label>3</label>Hospital of Xi&#x02019;an Jiaotong University, Xi&#x02019;an, 710061, China</aff><aff id="AFF4"><label>4</label>Wuxi School of Medicine, Jiangnan University, Wuxi, China</aff><author-notes><corresp id="COR1"><bold>Correspondence:</bold> Xiaofeng Dai (<email>1281423490@qq.com</email>)</corresp></author-notes><pub-date pub-type="collection"><day>31</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="epub" iso-8601-date="2020-01-10"><day>10</day><month>1</month><year>2020</year></pub-date><volume>40</volume><issue>1</issue><elocation-id>BSR20192546</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2019</year></date><date date-type="rev-recd"><day>19</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2019</year></date><date date-type="accepted-manuscript"><day>24</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s).</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).</license-p></license></permissions><self-uri xlink:href="bsr-40-bsr20192546.pdf"/><abstract><title>Abstract</title><p><italic>RAD50</italic> is commonly depleted in basal-like breast cancer with concomitant absence of <italic>INPP4B</italic> and several tumor suppressors such as <italic>BRCA1</italic> and <italic>TP53</italic>. Our previous study revealed that <italic>INPP4B</italic> and <italic>RAD50</italic> interact and such an interaction is associated with breast cancer survival at the transcriptional, translational and genomic levels. In the present study, we explored single nucleotide polymorphisms (SNPs) of these two genes that have synergistic effects on breast cancer survival to decipher mechanisms driving their interactions at the genetic level. The Cox&#x02019;s proportional hazards model was used to test whether SNPs of these two genes are interactively associated with breast cancer survival, following expression quantitative trait loci (eQTL) analysis and functional investigations. Our study revealed two disease-associating blocks, each encompassing five and two non-linkage disequilibrium linked SNPs of <italic>INPP4B</italic> and <italic>RAD50</italic>, respectively. Concomitant presence of any rare homozygote from each disease-associating block is synergistically prognostic of poor breast cancer survival. Such synergy is mediated via bypassing pathways controlling cell proliferation and DNA damage repair, which are represented by INPP4B and RAD50. Our study provided genetic evidence of interactions between <italic>INPP4B</italic> and <italic>RAD50</italic>, and deepened our understandings on the orchestrated genetic machinery governing tumor progression.</p></abstract><kwd-group><kwd>Breast cancer</kwd><kwd>INPP4B</kwd><kwd>RAD50</kwd><kwd>SNP</kwd></kwd-group><counts><page-count count="11"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>As the second leading cause of deaths worldwide, great attention has been paid in order to reveal the underlying factors that drive the genesis of cancer [<xref rid="B1" ref-type="bibr">1</xref>]. Evidences showed that various factors are linked with growth and development of different types of cancer which include mutation [<xref rid="B2" ref-type="bibr">2</xref>], radiation [<xref rid="B3" ref-type="bibr">3</xref>], inflammatory bowel disease [<xref rid="B4" ref-type="bibr">4</xref>], viral [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>] and bacterial infection [<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B7" ref-type="bibr">7</xref>]. Breast cancer is the leading cause of deaths among women with the annual mortality rate being estimated over 570000 worldwide [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>]. Most breast cancers are sporadic cancers caused by accumulation of acquired yet uncorrected genetic alterations in somatic genes, while other cases are associated with inherited genetic changes in disease predisposing genes [<xref rid="B10" ref-type="bibr">10</xref>]. As one of the most common types of genetic variations in human genome, single nucleotide polymorphisms (SNPs) in genes involved in DNA damage repair, metabolism, carcinogen metabolism, cell-cycle control, apoptosis and immunity are likely to be associated with genetic susceptibility to various cancer types including breast cancer [<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>]. So far, common SNPs can account for 18% of breast cancer familial risk among women [<xref rid="B13" ref-type="bibr">13</xref>].</p><p>SNPs can be located in either coding or non-coding regions. SNPs located in the coding regions are assumed to be able to affect protein production and functionalities, and thus more likely to cause phenotypic changes [<xref rid="B14" ref-type="bibr">14</xref>]. SNPs located in the non-coding region are less toxic and more easily to be inherited. However, recent advances suggest that SNPs in the non-coding regions may also play a functional role including, e.g. RNA splicing, genome imprinting, long non-coding RNAs binding etc [<xref rid="B11" ref-type="bibr">11</xref>].</p><p><italic>RAD50</italic> is crucial to maintain genomic integrity and prevent tumorigenesis [<xref rid="B15" ref-type="bibr">15</xref>]. It is a key protein involved in DNA double-strand breaks repair and frequently deleted in basal-like breast tumors [<xref rid="B16" ref-type="bibr">16</xref>]. <italic>RAD50</italic> is a breast cancer susceptibility gene associated with genomic instability [<xref rid="B17" ref-type="bibr">17</xref>]. Loss of <italic>RAD50</italic> often co-occurs with deletion of one or more tumor suppressor genes <italic>BRCA1, TP53, PTEN, RB1</italic> and <italic>INPP4B</italic> [<xref rid="B18" ref-type="bibr">18</xref>]. <italic>INPP4B</italic> is involved in the control of cell proliferation, cell metabolism and apoptosis [<xref rid="B19" ref-type="bibr">19</xref>]. <italic>INPP4B</italic> resides in the PI3K/Pten/mTOR pathway which is a complex network that controls cell proliferation and survival and is deregulated in over 70% of breast cancers [<xref rid="B20" ref-type="bibr">20</xref>]. Moreover, <italic>INPP4B</italic> deficiency affects <italic>BRCA1, ATM</italic> and <italic>ATR</italic> protein stability, which may lead to the defect of DNA repair machinery and, ultimately, uncontrolled cancer growth [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>We have previously demonstrated that <italic>INPP4B</italic> and <italic>RAD50</italic> collectively affect breast cancer survival at the transcriptional and translational levels [<xref rid="B22" ref-type="bibr">22</xref>]. To further identify the synergies between <italic>INPP4B</italic> and <italic>RAD50</italic> on clinical consequences at the genetic level, we are motivated to identify the relevant disease-associating SNPs that affect the expression of each gene and are collectively prognostic of the clinical outcome of breast cancer patients.</p></sec><sec sec-type="materials|methods" id="sec2"><title>Materials and methods</title><p>The workflow of the methods is presented in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Schematic diagram of the analytic flow in the present study</title><p>The purple oval and blue rhombi represent the SNPs in TCGA and analytical methods, respectively. Rectangle represents obtained results at each stage of analysis, where green represents &#x02018;genes&#x02019;, yellow represents &#x02018;SNPs&#x02019;, bronze represents &#x02018;block&#x02019;. Abbreviation: TCGA, The Cancer Genome Atlas.</p></caption><graphic xlink:href="bsr-40-bsr20192546-g1"/></fig><sec id="sec2-1"><title>Datasets</title><p>We retrieved 184485 SNPs of <italic>INPP4B</italic> and 19974 SNPs of <italic>RAD50</italic> from the dbSNP NCBI database [<xref rid="B23" ref-type="bibr">23</xref>]. Among these SNPs, 269 SNPs of <italic>INPP4B</italic> and 15 SNPs of <italic>RAD50</italic> were mapped to the Affymetrix SNP6.0 Array which was used in The Cancer Genome Atlas (TCGA). Information of the 284 SNPs covering 501 samples was retrieved from TCGA (<ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov">http://cancergenome.nih.gov</ext-link>) and used for the downstream analysis. The gene expression data were retrieved from TCGA bioportal (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/">http://www.cbioportal.org/</ext-link>), which contained 20440 genes and 1102 samples.</p><p>The GSE24450 dataset containing gene expression and clinical information of 183 breast tumors from the Helsinki University Central Hospital was retrieved from GEO with 10-year follow up information included in this dataset [<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>].</p><p>TCGA cohort and GEO cohort were merged followed by log2 transformation and batch correction using the &#x02018;ComBat&#x02019; function in &#x02018;sva&#x02019; package (version 3.30.1) in R [<xref rid="B26" ref-type="bibr">26</xref>]. These merged data were used in expression Quantitative Trait Loci (eQTL) analysis and pair-wise expression survival analysis.</p></sec><sec id="sec2-2"><title>Pair-wise SNP survival analysis</title><p>We conducted breast cancer overall survival (OS) analysis on interactions between SNPs of <italic>INPP4B</italic> and <italic>RAD50</italic> using the Cox&#x02019;s proportional hazard model. The recessive model was used in the pair-wise SNP association analysis, where the heterozygote was combined with the common homozygote assuming that the disease-associating phenotype is caused by the concomitant presence of both rare alleles in both interacting SNPs. The 10-year breast cancer OS survival analysis utilizing the &#x02018;survival&#x02019; package (version 2.44.1.1) [<xref rid="B27" ref-type="bibr">27</xref>]. An SNP pair was considered interactive if the <italic>P</italic>-value of the Cox repression model was &#x0003c;0.05, the <italic>P</italic>-value of the interaction term was &#x0003c;0.05, and the number of iterations showing the model convergence rate was &#x0003c;10.</p></sec><sec id="sec2-3"><title>Block-wise SNP survival analysis</title><p>Haplotype block refers to the inheritance of a cluster of SNPs [<xref rid="B28" ref-type="bibr">28</xref>]. LDlink (<ext-link ext-link-type="uri" xlink:href="https://analysistools.nci.nih.gov/LDlink/">https://analysistools.nci.nih.gov/LDlink/</ext-link>) was used to calculate pair-wise linkage disequilibrium (LD) among SNPs associated with the same gene. SNPs with <italic>r</italic><sup>2</sup> greater than 0.8 were considered linked to the same haplotype. Non-LD linked SNPs were considered independent. We randomly selected one SNP among its LD-linked peers, and grouped independent SNPs of <italic>INPP4B</italic> and <italic>RAD50</italic> into distinct disease-associating blocks, respectively.</p><p>Block-wise survival analysis was performed between the disease-associating blocks of <italic>INPP4B</italic> and <italic>RAD50</italic>, respectively, assuming that the presence of the rare allele of any SNP within the block contributes equally to the synergistic clinical association. PredictSNP2 [<xref rid="B29" ref-type="bibr">29</xref>], a unified platform for predicting SNP effect, was employed to analyze the functionalities of non-LD linked SNPs. SNP2TFBS tool was used to check whether an SNP affects transcription factor binding site affinity [<xref rid="B30" ref-type="bibr">30</xref>].</p></sec><sec id="sec2-4"><title>eQTL analysis</title><p>To identify genes whose expressions are significantly affected by the identified SNPs in each disease-associating block or the disease-associating block as a whole, we conducted the eQTL analysis. In single SNP eQTL analysis, gene expression was modeled against the allele status of an SNP using logistic regression. SNPs with a <italic>P</italic>-value of the linear model &#x0003c;0.01 were considered eQTLs of a gene. SNPs significantly affecting patient OS and expression of the gene it resides in were defined as disease-associating SNPs. In block-wise eQTL analysis, the allele statuses were combined and binarized such that concomitant presence of all rare alleles in a disease-associating block was considered as &#x02018;1&#x02019; and block alleles containing any common allele was considered as &#x02018;0&#x02019;. Top genes filtered using <italic>P</italic>&#x0003c;0.01 and the coefficient &#x003b2; &#x0003e; 0.3 from the linear regression were selected as being significantly affected by the disease-associating block at the transcriptional level.</p></sec><sec id="sec2-5"><title>Pair-wise expression survival analysis</title><p>We conducted breast cancer OS analysis on interactions between the expressions of a gene identified in the eQTL analysis to identify the quantitative association of a gene and its eQTLs using the Cox&#x02019;s proportional hazard model. Gene expression of a gene was binarized by its median level, and the 10-year breast cancer OS survival analysis was conducted using the &#x02018;survival&#x02019; package [<xref rid="B27" ref-type="bibr">27</xref>]. A gene pair was considered interactive if the <italic>P</italic>-values of the Cox repression model and the interaction term were both 0.05.</p><p>In addition, the expression of one gene was stratified by that of another to assess the influence of one gene on another or the interactions between two genes at the transcriptional level. ANOVA test was used to assess the statistical significance with <italic>P</italic>&#x0003c;0.05 being the threshold.</p></sec><sec id="sec2-6"><title>Functional analysis</title><p>In order to investigate the functional consequences introduced by SNPs, pathway enrichment analysis was performed using genes affected by SNPs with statistical significance. Gene Ontology (GO) term, KEGG pathway and Reactome pathway were enriched using the web interface &#x02018;Metascape&#x02019; [<xref rid="B31" ref-type="bibr">31</xref>]. Genes identified from the enriched pathways were collected for gene regulatory network construction using GeneMANIA (<ext-link ext-link-type="uri" xlink:href="http://www.genemania.org">http://www.genemania.org</ext-link>) [<xref rid="B32" ref-type="bibr">32</xref>]. GeneMANIA uses the label propagation algorithm to predict gene&#x02013;gene interactions at 7 levels (co-expression, co-localization, genetic interaction, physical interaction, shared protein domain, pathway and predicted) where interactions from genetic interaction are selected to construct our network. It outputs a regulatory network using the user-defined gene list based on databases and publications from multiple resources [<xref rid="B32" ref-type="bibr">32</xref>].</p></sec></sec><sec sec-type="results" id="sec3"><title>Results and discussion</title><sec id="sec3-1"><title>SNPs of <italic>INPP4B</italic> and <italic>RAD50</italic> synergistically affect breast cancer survival</title><p>Multivariate Cox regression model was constructed to perform pair-wise interaction analysis using SNPs of <italic>INPP4B</italic> and <italic>RAD50</italic> on breast cancer OS. The results revealed nine SNPs, five from <italic>INPP4B</italic> (rs1219269, rs17016021, rs2636683, rs336298, rs9996933) and four from <italic>RAD50</italic> (rs3798134, rs3798135, rs2040704, rs2706347), having significant association with patient clinical outcome (<xref rid="T1" ref-type="table">Table 1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>SNPs significantly affecting breast cancer OS</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">SNP</th><th align="left" rowspan="1" colspan="1">Position</th><th align="left" rowspan="1" colspan="1">Alleles</th><th align="left" rowspan="1" colspan="1">MAF</th><th align="left" rowspan="1" colspan="1">Consequence</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic>RAD50</italic></td><td rowspan="1" colspan="1">rs3798134</td><td rowspan="1" colspan="1">chr5:132629487</td><td rowspan="1" colspan="1">G&#x0003e;A</td><td rowspan="1" colspan="1">0.2564</td><td rowspan="1" colspan="1">Intron variant</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">rs3798135</td><td rowspan="1" colspan="1">chr5:132629417</td><td rowspan="1" colspan="1">C&#x0003e;T</td><td rowspan="1" colspan="1">0.2556</td><td rowspan="1" colspan="1">Intron variant</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">rs2040704</td><td rowspan="1" colspan="1">chr5:132637485</td><td rowspan="1" colspan="1">A&#x0003e;G</td><td rowspan="1" colspan="1">0.3297</td><td rowspan="1" colspan="1">Intron variant</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">rs2706347</td><td rowspan="1" colspan="1">chr5:132569425</td><td rowspan="1" colspan="1">G&#x0003e;T</td><td rowspan="1" colspan="1">0.3095</td><td rowspan="1" colspan="1">Intron variant</td></tr><tr><td rowspan="1" colspan="1"><italic>INPP4B</italic></td><td rowspan="1" colspan="1">rs1219269</td><td rowspan="1" colspan="1">chr4:142174118</td><td rowspan="1" colspan="1">A&#x0003e;T</td><td rowspan="1" colspan="1">0.2726</td><td rowspan="1" colspan="1">Intron variant</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">rs17016021</td><td rowspan="1" colspan="1">chr4:142373233</td><td rowspan="1" colspan="1">A&#x0003e;T</td><td rowspan="1" colspan="1">0.0260</td><td rowspan="1" colspan="1">Intron variant</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">rs2636683</td><td rowspan="1" colspan="1">chr4:142176930</td><td rowspan="1" colspan="1">C&#x0003e;T</td><td rowspan="1" colspan="1">0.3758</td><td rowspan="1" colspan="1">Intron variant</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">rs336298</td><td rowspan="1" colspan="1">chr4:142094199</td><td rowspan="1" colspan="1">T&#x0003e;C</td><td rowspan="1" colspan="1">0.4002</td><td rowspan="1" colspan="1">Intron variant</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">rs9996933</td><td rowspan="1" colspan="1">chr4:142087174</td><td rowspan="1" colspan="1">T&#x0003e;C</td><td rowspan="1" colspan="1">0.2676</td><td rowspan="1" colspan="1">Intron variant</td></tr></tbody></table><table-wrap-foot><fn><p>&#x02018;MAF&#x02019; represents minor allele frequency.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-2"><title>Concomitant presence of rare homozygotes of SNPs from disease-associating blocks is associated with poor breast cancer OS</title><p>The four identified SNPs of <italic>RAD50</italic> are linked to two haplotypes, i.e. the <italic>r</italic><sup>2</sup> between rs2706347 and rs2040704 is 0.911, and that between rs3798135 and rs3798134 is 0.999 (<xref ref-type="fig" rid="F2">Figure 2</xref>A). All SNPs of <italic>INPP4B</italic> are non-LD linked (<xref ref-type="fig" rid="F2">Figure 2</xref>B).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Interactions between SNPs in <italic>INPP4B</italic> and <italic>RAD50</italic></title><p>Heatmaps showing LD associations among SNPs of (<bold>A</bold>) <italic>RAD50</italic> and (<bold>B</bold>) <italic>INPP4B</italic>. OS analysis of (<bold>C</bold>) interactions of disease-associating block of <italic>RAD50</italic>, (<bold>D</bold>) disease-associating block of <italic>INPP4B</italic>, and (<bold>E</bold>) disease-associating blocks of <italic>INPP4B</italic> and <italic>RAD50</italic>. In subgraph (<bold>E</bold>), green curve represents concomitant presence of the rare homozygote of SNPs in both disease-associating blocks of <italic>INPP4B</italic> and <italic>RAD50</italic>; pink curve represents concomitant presence of the common homozygote of SNPs in both disease-associating blocks of <italic>INPP4B</italic> and <italic>RAD50</italic>; purple curve and bronze curve each represents the presence of the rare homozygote of SNPs in the disease-associating blocks of <italic>INPP4B</italic> and <italic>RAD50</italic>, respectively. The x-axis indicates the follow-up time, and the vertical axis shows the cumulative OS of breast cancer patients.</p></caption><graphic xlink:href="bsr-40-bsr20192546-g2"/></fig><p>Two disease-associating blocks were constructed where one SNP was randomly selected if multiple SNPs resided in one haplotype. That is, the <italic>INPP4B</italic> block includes rs336298, rs9996933, rs1219269, rs2636683, rs17016021, and the <italic>RAD50</italic> block contains rs3798134 and rs2040704. The results of the block-wise OS analysis using recessive model indicated that concomitant presence of the rare homozygote of any SNPs from each disease-associating block is associated with significantly reduced breast cancer OS (<xref ref-type="fig" rid="F2">Figure 2</xref>E). The presence of all common homozygotes in either <italic>INPP4B</italic> or <italic>RAD50</italic> is sufficient to rescue patient clinical outcome.</p><p>On the other hand, either of the two disease-associating blocks drives significant differences on patient OS (<xref ref-type="fig" rid="F2">Figure 2</xref>C,D), suggesting that it is the interaction between the two disease-associating blocks that differentiate breast cancer clinical outcome but not either one of the two blocks.</p><p>We performed the eQTL analysis followed by the pair-wise expression survival analysis, which revealed that concomitant presence of the rare allele in the disease-associating block of <italic>INPP4B</italic> was positively associated with low <italic>BCKDHB</italic> expression that is risky (<italic>P</italic>=0.023, HR = 0.81, <xref ref-type="fig" rid="F3">Figure 3</xref>), and that of <italic>RAD50</italic> was positively associated with <italic>RMND5A</italic> and <italic>PWP2</italic> high expression which were risky (<italic>RMND5A</italic>: <italic>P</italic>=0.0005, HR = 1.39; <italic>PWP2</italic>: <italic>P</italic>=0.029, HR = 1.23, <xref ref-type="fig" rid="F3">Figure 3</xref>). In addition, <italic>RMND5A</italic> or <italic>PWP2</italic> overexpression was associated with breast cancer clinical outcome under <italic>BCKDHB</italic> low-expression, which were both risky (<italic>RNMD5A</italic> and <italic>BCKDHB</italic>: <italic>P</italic>=0.0025, HR = 1.48; <italic>PWP2</italic> and <italic>BCKDHB</italic>: <italic>P</italic>=0.03, HR = 1.32, <xref ref-type="fig" rid="F4">Figure 4</xref>), and such a prognostic value diminishes under <italic>BCKDHB</italic> high expression. Therefore, the joint prognostic value of the two disease-associating blocks was in agreement with those from the pair-wise joint expression between <italic>BCKDHB</italic> and <italic>RMND5A, BCKDHB</italic> and <italic>PWP2.</italic> Further, <italic>BCKDHB</italic> interacts with <italic>INPP4B</italic>, where low <italic>BCKDHB</italic> under low <italic>INPP4B</italic> expression was risky (<italic>P</italic>=0.03, HR = 0.75, <xref ref-type="fig" rid="F3">Figure 3</xref>), high <italic>RMND5A</italic> or <italic>PWP2</italic> was risky under high <italic>RAD50</italic> expression (<italic>RMND5A</italic>: <italic>P</italic>=0.001, HR = 1.54; <italic>PWP2</italic>: 0.015, HR = 1.37, <xref ref-type="fig" rid="F3">Figure 3</xref>). On the other hand, low <italic>INPP4B</italic> and high <italic>RAD50</italic> expression are risky (<italic>P</italic>=0.00296, HR = 3.15, <xref ref-type="fig" rid="F4">Figure 4</xref>), and high INPP4B and low RAD50 convey unfavorable clinical outcome (<italic>P</italic>=0.03, HR = 1.6, <xref ref-type="fig" rid="F4">Figure 4</xref>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Associations between each disease-associating block and the corresponding gene</title><p>(<bold>A</bold>) Correlation between <italic>RMND5A</italic> gene expression and allele status of the <italic>RAD50</italic> disease-associating block. The prognostic value of <italic>RMND5A</italic> on breast cancer OS (<bold>B</bold>) alone, (<bold>C</bold>) under low <italic>RAD50</italic> gene expression, (<bold>D</bold>) under high <italic>RAD50</italic> gene expression. (<bold>E</bold>) Correlation between <italic>PWP2</italic> gene expression and allele status of the <italic>RAD50</italic> disease-associating block. The prognostic value of <italic>PWP2</italic> on breast cancer OS (<bold>F</bold>) alone, (<bold>G</bold>) under low <italic>RAD50</italic> gene expression, (<bold>H</bold>) under high <italic>RAD50</italic> gene expression. (<bold>I</bold>) Correlation between <italic>BCKDHB</italic> gene expression and allele status of the <italic>INPP4B</italic> disease-associating block. The prognostic value of <italic>BCKDHB</italic> on breast cancer OS (<bold>J</bold>) alone, (<bold>K</bold>) under low <italic>INPP4B</italic> gene expression, (<bold>L</bold>) under high <italic>INPP4B</italic> gene expression.</p></caption><graphic xlink:href="bsr-40-bsr20192546-g3"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Pair-wise gene interactions</title><p>(<bold>A</bold>) The prognostic value of <italic>INPP4B</italic> gene expression on breast cancer OS under high and low <italic>RAD50</italic> expression. (<bold>B</bold>) The prognostic value of <italic>RAD50</italic> gene expression on breast cancer OS under high and low <italic>INPP4B</italic> expression. (<bold>C</bold>) The prognostic value of <italic>PWP2</italic> gene expression on breast cancer OS under high and low <italic>BCKDHB</italic> expression. (<bold>D</bold>) The prognostic value of <italic>RMND5A</italic> gene expression on breast cancer OS under high and low <italic>BCKDHB</italic> expression.</p></caption><graphic xlink:href="bsr-40-bsr20192546-g4"/></fig></sec><sec id="sec3-3"><title>Gene function analysis of non-LD linked SNPs</title><p>We obtained 89 genes from the eQTL analysis, whose expression were significantly affected by the allele status of identified non-LD linked SNPs. GO and KEGG gene enrichment analysis showed that these genes were significantly enriched in &#x02018;PI3K/AKT activation process&#x02019; (<xref ref-type="fig" rid="F5">Figure 5</xref>A).</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Pathway enrichment and network construction using genes quantitatively associated with <italic>INPP4B</italic> and <italic>RAD50</italic> disease-associating blocks</title><p>(<bold>A</bold>) GO and KEGG enrichment analysis. (<bold>B</bold>) Network constructed using GeneMania where only genetic interactions were preserved.</p></caption><graphic xlink:href="bsr-40-bsr20192546-g5"/></fig><p>The regulatory network involving <italic>INPP4B</italic> and <italic>RAD50</italic> showed that <italic>BCKDHB</italic> and <italic>INPP4B</italic>, as well as <italic>RMND5A</italic> and <italic>RAD50</italic> have direct genetic interactions, PWP2 and RAD50 have indirect genetic interactions via <italic>ALDH1L1</italic> and <italic>NAA40</italic> (<xref ref-type="fig" rid="F5">Figure 5</xref>B).</p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Through pair-wise and block-wise interactive OS analyses on SNPs of <italic>INPP4B</italic> and <italic>RAD50</italic>, we identified two disease-associating blocks, each containing five SNPs (<italic>INPP4B</italic>) and two SNPs (<italic>RAD50</italic>), respectively, which synergistically affect breast cancer clinical outcome. Specifically, concomitant presence of the rare homozygotes of all SNPs within each block is associated with decreased breast cancer OS, while neither one of these blocks differentiate breast cancer clinical outcome with statistical significance. Both <italic>RAD50</italic> and <italic>INPP4B</italic> are crucial to maintain genomic integrity and prevent tumorigenesis [<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>], and co-deletion of both genes commonly co-occurs in many types of cancers including breast cancer [<xref rid="B10" ref-type="bibr">10</xref>]. Our results further consolidate our understandings on cells and carcinogenesis, i.e. cells are robust systems having multiple ways to suppress tumorigenesis, and carcinogenesis is likely to occur when all tumor suppressive systems are dysfunctional.</p><p>The two disease-associating SNP blocks were each associated with the expression of genes that interacted with <italic>INPP4B</italic> and <italic>RAD50</italic>, respectively, with consistent directions regarding their prognostic values. For instance, concomitant presence of rare alleles in the disease-associating block of <italic>INPP4B</italic> was positively associated low <italic>BCKDHB</italic> expression, and the rare status of the <italic>RAD50</italic> disease-associating block was positively correlated with high <italic>RMND5A</italic> or <italic>PWP2</italic> expression. Importantly, concomitant presence of rare statuses of <italic>INPP4B</italic> and <italic>RAD50</italic> was risky, which was consistent with joint low <italic>BCKDHB</italic> and high <italic>RMND5A</italic> or <italic>PWP2</italic> expression (risky). This makes it possible to associate interactions at the genetic level with interactions at the gene expression level regarding clinical outcomes. Meanwhile, <italic>BCKDHB</italic> interacted with <italic>INPP4B, RMND5A</italic> and <italic>PWP2</italic> each interacted with <italic>RAD50</italic>, and <italic>INPP4B</italic> interacted with <italic>RAD50</italic> regarding clinical associations, and these clinical associations shared consistent directions. That is, low <italic>BCKDHB</italic> and low <italic>INPP4B</italic> is risky, high <italic>RMND5A</italic> and high <italic>RAD50</italic> is risky, low <italic>BCKDHB</italic> and high <italic>RMND5A</italic> is risky, low <italic>INPP4B</italic> and high <italic>RAD50</italic>, where the clinical association of each of these genes is transferable among these pair-wise joint clinical associations. Provided the strong correlation between the <italic>INPP4B</italic> disease-associating block and <italic>BCKDHB</italic>, and <italic>RAD50</italic> disease-associating block and <italic>RMND5A</italic>, it is highly likely that <italic>BCKDHB</italic> and <italic>RMND5A</italic> reflected and/or mediated interactions between <italic>INPP4B</italic> and <italic>RAD50</italic> at the gene expression level which also applies for pair <italic>BCKDHB</italic> and <italic>PWP2</italic>. Indeed, we found from GeneMania that <italic>BCKDHB</italic> had genetic interactions with <italic>INPP4B</italic> and <italic>RAD50</italic>, respectively, which were previously reported by [<xref rid="B32" ref-type="bibr">32</xref>], and <italic>RMND5A</italic> and <italic>PWP2</italic> had known genetic interactions with RAD50, which were in agreement with what we observed in the present study and supported our findings. Interestingly, <italic>BCKDHB</italic> was also genetically associated with TGF&#x003b2;1 that plays critical roles in TGF&#x003b2; signaling and responsible for cancer stemness; and <italic>PWP2</italic> genetically interacted with <italic>RAD50</italic> via <italic>ALDH1L1</italic> that is associated with neural stem cells <italic>in vivo</italic> [<xref rid="B33" ref-type="bibr">33</xref>], suggesting a trilateral connection among uncontrolled cell proliferation (as represented by INPP4B and PI3K/Pten pathway), DNA damage repair (as represented here by RAD50), and cancer stemess (as featured by TGF&#x003b2;-mediated signaling and ALDH1L1).</p><p>Among the three genes mediating interactions between <italic>INPP4B</italic> and <italic>RAD50</italic>, only <italic>RMND5A</italic> has known evidence which is a tumor vasculature-associated gene with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells [<xref rid="B34" ref-type="bibr">34</xref>]. <italic>BCKDHB</italic> encodes the E1 &#x003b2; subunit of branched-chain keto acid dehydrogenase and is a multienzyme complex associated with the inner membrane of mitochondria [<xref rid="B35" ref-type="bibr">35</xref>]. <italic>PWP2</italic> is involved in humoral immunity [<xref rid="B36" ref-type="bibr">36</xref>]. Their relevance with cancer initiation and progression is worthy to be investigated. <italic>INPP4B</italic> and <italic>RAD50</italic> were also genetically connected via <italic>TRIM47</italic> and <italic>TRIM65</italic>, and TRIM family proteins are known players in innate immunity, and have recognized roles in carcinogensis [<xref rid="B37" ref-type="bibr">37</xref>]. These together suggest the involvement of immune response, metabolism and angiogenesis in mediating synergies between <italic>INPP4B</italic> and <italic>RAD50</italic>.</p><p>We further identified disease-associating SNPs in both disease-associating blocks. That is, both rs2040740 residing in the intron of <italic>RAD50</italic> and rs17016021 from the intron of <italic>INPP4B</italic> are deleterious; and the rare allele of rs2040740 is significantly associated with reduced <italic>RAD50</italic> expression. The minor allele frequency (MAF) of the <italic>RAD50</italic> disease-associating SNP (rs2040704) is the highest among all SNPs in the <italic>RAD50</italic> disease-associating block, which is &#x0223c;0.33 (<xref rid="T1" ref-type="table">Table 1</xref>), suggesting its prevalence. Actually all SNPs in the <italic>RAD50</italic> disease-associating block have a relatively high prevalence (i.e. ranging from 0.25 to 0.33, <xref rid="T1" ref-type="table">Table 1</xref>), indicating that the pathway represented by <italic>RAD50</italic> is more likely to be dysfunctional. However, the MAF of the <italic>INPP4B</italic> disease-associating SNP (rs17016021) is rather rare, i.e. 0.026 (<xref rid="T1" ref-type="table">Table 1</xref>), suggesting that dysfunction of the pathway represented by <italic>INPP4B</italic> is less likely to occur whose mutation functions as a pivotal switch toward enhanced cancer cell proliferation potential.</p><p>Importantly, PCR assays testing the polymorphisms of both SNPs in clinical materials that are associated with differential clinical outcomes are necessary before translating our discovery into clinics, and this would be our next endeavor to make.</p><p>As aforementioned, we hypothesize that synergies created from the identified disease-associating blocks of <italic>INPP4B</italic> and <italic>RAD50</italic> are related to cell progression and mutation accumulation that ultimately affect patient clinical outcome from our eQTL and pathway enrichment analyses. Such synergies may also involve altered immune response and cancer stemness. However, the exact underlying mechanism still awaits to be explored and experimentally validated.</p></sec><sec sec-type="conclusion" id="sec5"><title>Conclusion</title><p>We identified two disease-associating blocks of <italic>INPP4B</italic> and <italic>RAD50</italic>, each containing five and two SNPs, respectively. Concomitant presence of any rare homozygote from each of the two disease-associating blocks is associated with decreased breast cancer survival, through disenabling breast cancer cell proliferation and DNA repair signaling pathways as represented by <italic>INPP4B</italic> and <italic>RAD50</italic>. Our study provides genetic evidence on the prognostic synergies between <italic>INPP4B</italic> and <italic>RAD50</italic> on breast cancer outcome and deepens our understandings toward cancer progression that ultimately facilitates cancer precision medicine.</p></sec></body><back><sec id="sec6"><title>Author Contribution</title><p>X.C. conducted the computational analysis and R.T. helped in this process. X.D. designed and supervised the present study. X.C. and X.D. prepared the manuscript. X.D. and J.Z. co-funded this work.</p></sec><sec id="sec7" sec-type="COI-statement"><title>Competing Interests</title><p>The authors declare that there are no competing interests associated with the manuscript.</p></sec><sec id="sec8" sec-type="funding"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China [grant number 81972789]; the National Science and Technology Major Project [grant number 2018ZX10302205-004-002]; the Six Talent Peaks Project in Jiangsu Province [grant number SWYY-128]; and the Technology Development Funding of Wuxi [grant number WX18IVJN017]. These funding sources have no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></sec><sec id="sec9" sec-type="COI-statement"><title>Ethical Approval</title><p>This article does not contain any studies with human participants or animals performed by any of the authors.</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="G1">eQTL</term><def><p>expression Quantitative Trait Loci</p></def></def-item><def-item><term id="G2">GEO</term><def><p>Gene Expression Omnibus</p></def></def-item><def-item><term id="G3">GO</term><def><p>Gene Ontology</p></def></def-item><def-item><term id="G4">HR</term><def><p>Hazard Ratio</p></def></def-item><def-item><term id="G5">KEGG</term><def><p>Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term id="G6">LD</term><def><p>linkage disequilibrium</p></def></def-item><def-item><term id="G7">MAF</term><def><p>minor allele frequency</p></def></def-item><def-item><term id="G8">OS</term><def><p>overall survival</p></def></def-item><def-item><term id="G9">SNP</term><def><p>single nucleotide polymorphism</p></def></def-item><def-item><term id="G10">TCGA</term><def><p>The Cancer Genome Atlas</p></def></def-item></def-list></glossary><ref-list id="ref1"><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blackadar</surname><given-names>C.B.</given-names></name></person-group> (<year>2016</year>) <article-title>Historical review of the causes of cancer</article-title>. <source>World J. Clin. Oncol.</source>
<volume>7</volume>, <fpage>54</fpage>&#x02013;<lpage>86</lpage>
<pub-id pub-id-type="doi">10.5306/wjco.v7.i1.54</pub-id><pub-id pub-id-type="pmid">26862491</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>M.J.</given-names></name>, <name name-style="western"><surname>Synnott</surname><given-names>N.C.</given-names></name> and <name name-style="western"><surname>Crown</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>) <article-title>Mutant p53 in breast cancer: potential as a therapeutic target and biomarker</article-title>. <source>Breast Cancer Res. Treat.</source>
<volume>170</volume>, <fpage>213</fpage>&#x02013;<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-018-4753-7</pub-id><pub-id pub-id-type="pmid">29564741</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Angele</surname><given-names>S.</given-names></name></person-group> (<year>1999</year>) <article-title>Radiation, DNA damage and cancer</article-title>. <source>Mol. Med. Today</source>
<volume>5</volume>, <fpage>157</fpage>&#x02013;<lpage>164</lpage>
<pub-id pub-id-type="doi">10.1016/S1357-4310(99)01435-5</pub-id><pub-id pub-id-type="pmid">10203748</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>) <article-title>Potential role of <italic>Escherichia coli</italic> DNA mismatch repair proteins in colon cancer</article-title>. <source>Crit. Rev. Oncol. Hematol.</source>
<volume>96</volume>, <fpage>475</fpage>&#x02013;<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1016/j.critrevonc.2015.05.002</pub-id><pub-id pub-id-type="pmid">26014615</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zakariah</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Rolfo</surname><given-names>C.</given-names></name><etal>et al</etal>.</person-group> (<year>2017</year>) <article-title>Prediction of mycoplasma hominis proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology</article-title>. <source>Oncotarget</source>
<volume>8</volume>, <fpage>30830</fpage>&#x02013;<lpage>30843</lpage>
<pub-id pub-id-type="pmid">27027344</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshamsan</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Imran</surname><given-names>A.</given-names></name><etal>et al</etal>.</person-group> (<year>2017</year>) <article-title>Prediction of <italic>Chlamydia pneumoniae</italic> protein localization in host mitochondria and cytoplasm and possible involvements in lung cancer etiology: a computational approach</article-title>. <source>Saudi Pharm. J.</source>
<volume>25</volume>, <fpage>1151</fpage>&#x02013;<lpage>1157</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsps.2017.05.007</pub-id><pub-id pub-id-type="pmid">30166903</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Imran</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>A.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Bacterial imbalance and gut pathologies: association and contribution of E. coli in inflammatory bowel disease</article-title>. <source>Crit. Rev. Clin. Lab. Sci.</source>
<volume>56</volume>, <fpage>1</fpage>&#x02013;<lpage>17</lpage><pub-id pub-id-type="pmid">30373492</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeSantis</surname><given-names>C.E.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gaudet</surname><given-names>M.M.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Breast cancer statistics, 2019</article-title>. <source>CA Cancer J. Clin.</source>
<volume>69</volume>, <fpage>438</fpage>&#x02013;<lpage>451</lpage>
<pub-id pub-id-type="doi">10.3322/caac.21583</pub-id><pub-id pub-id-type="pmid">31577379</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.S.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z.N.</given-names></name><etal>et al</etal>.</person-group> (<year>2017</year>) <article-title>Risk factors and preventions of breast cancer</article-title>. <source>Int. J. Biol. Sci.</source>
<volume>13</volume>, <fpage>1387</fpage>&#x02013;<lpage>1397</lpage>
<pub-id pub-id-type="doi">10.7150/ijbs.21635</pub-id><pub-id pub-id-type="pmid">29209143</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahdi</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Nassiri</surname><given-names>M.R.</given-names></name> and <name name-style="western"><surname>Nasiri</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>) <article-title>Hereditary genes and SNPs associated with breast cancer</article-title>. <source>Asian Pac. J. Cancer Prev.</source>
<volume>14</volume>, <fpage>3403</fpage>&#x02013;<lpage>3409</lpage>
<pub-id pub-id-type="doi">10.7314/APJCP.2013.14.6.3403</pub-id><pub-id pub-id-type="pmid">23886119</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><etal>et al</etal>.</person-group> (<year>2017</year>) <article-title>Single nucleotide polymorphisms and cancer susceptibility</article-title>. <source>Oncotarget</source>
<volume>8</volume>, <fpage>110635</fpage>&#x02013;<lpage>110649</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.22372</pub-id><pub-id pub-id-type="pmid">29299175</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>M.R.</given-names></name>, <name name-style="western"><surname>Marnellos</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Kammerer</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group> (<year>2004</year>) <article-title>Large-scale validation of single nucleotide polymorphisms in gene regions</article-title>. <source>Genome Res.</source>
<volume>14</volume>, <fpage>1664</fpage>&#x02013;<lpage>1668</lpage>
<pub-id pub-id-type="doi">10.1101/gr.2421604</pub-id><pub-id pub-id-type="pmid">15289484</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lilyquist</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ruddy</surname><given-names>K.J.</given-names></name>, <name name-style="western"><surname>Vachon</surname><given-names>C.M.</given-names></name><etal>et al</etal>.</person-group> (<year>2018</year>) <article-title>Common genetic variation and breast cancer risk-past, present, and future</article-title>. <source>Cancer Epidemiol. Biomark. Prev.</source>
<volume>27</volume>, <fpage>380</fpage>&#x02013;<lpage>394</lpage></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vage</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Lingaas</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>) <article-title>Single nucleotide polymorphisms (SNPs) in coding regions of canine dopamine- and serotonin-related genes</article-title>. <source>BMC Genet.</source>
<volume>9</volume>, <fpage>10</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2156-9-10</pub-id><pub-id pub-id-type="pmid">18226236</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>S.P.</given-names></name> and <name name-style="western"><surname>Pandita</surname><given-names>T.K.</given-names></name></person-group> (<year>2006</year>) <article-title>The cellular control of DNA double-strand breaks</article-title>. <source>J. Cell. Biochem.</source>
<volume>99</volume>, <fpage>1463</fpage>&#x02013;<lpage>1475</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.21067</pub-id><pub-id pub-id-type="pmid">16927314</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johannsdottir</surname><given-names>H.K.</given-names></name>, <name name-style="western"><surname>Jonsson</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Johannesdottir</surname><given-names>G.</given-names></name><etal>et al</etal>.</person-group> (<year>2006</year>) <article-title>Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors</article-title>. <source>Int. J. Cancer</source>
<volume>119</volume>, <fpage>1052</fpage>&#x02013;<lpage>1060</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.21934</pub-id><pub-id pub-id-type="pmid">16570289</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heikkinen</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Rapakko</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Karppinen</surname><given-names>S.M.</given-names></name><etal>et al</etal>.</person-group> (<year>2006</year>) <article-title>RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability</article-title>. <source>Carcinogenesis</source>
<volume>27</volume>, <fpage>1593</fpage>&#x02013;<lpage>1599</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgi360</pub-id><pub-id pub-id-type="pmid">16474176</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weigman</surname><given-names>V.J.</given-names></name>, <name name-style="western"><surname>Chao</surname><given-names>H.H.</given-names></name>, <name name-style="western"><surname>Shabalin</surname><given-names>A.A.</given-names></name><etal>et al</etal>.</person-group> (<year>2012</year>) <article-title>Basal-like breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival</article-title>. <source>Breast Cancer Res. Treat.</source>
<volume>133</volume>, <fpage>865</fpage>&#x02013;<lpage>880</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-011-1846-y</pub-id><pub-id pub-id-type="pmid">22048815</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>T.W.</given-names></name>, <name name-style="western"><surname>Rexer</surname><given-names>B.N.</given-names></name>, <name name-style="western"><surname>Garrett</surname><given-names>J.T.</given-names></name><etal>et al</etal>.</person-group> (<year>2011</year>) <article-title>Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer</article-title>. <source>Breast Cancer Res.</source>
<volume>13</volume>, <fpage>224</fpage>
<pub-id pub-id-type="doi">10.1186/bcr3039</pub-id><pub-id pub-id-type="pmid">22114931</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Knowles</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>O&#x02019;Toole</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>McNeil</surname><given-names>C.M.</given-names></name><etal>et al</etal>.</person-group> (<year>2010</year>) <article-title>PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality</article-title>. <source>Int. J. Cancer</source>
<volume>126</volume>, <fpage>1121</fpage>&#x02013;<lpage>1131</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.24831</pub-id><pub-id pub-id-type="pmid">19685490</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal>et al</etal>.</person-group> (<year>2015</year>) <article-title>Oncogenes and tumor suppressor genes: comparative genomics and network perspectives</article-title>. <source>BMC Genomics</source>
<volume>16</volume>, <fpage>S8</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2164-16-S7-S8</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Fagerholm</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><etal>et al</etal>.</person-group> (<year>2015</year>) <article-title>INPP4B and RAD50 have an interactive effect on survival after breast cancer</article-title>. <source>Breast Cancer Res. Treat.</source>
<volume>149</volume>, <fpage>363</fpage>&#x02013;<lpage>371</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-014-3241-y</pub-id><pub-id pub-id-type="pmid">25528023</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherry</surname><given-names>S.T.</given-names></name>, <name name-style="western"><surname>Ward</surname><given-names>M.H.</given-names></name>, <name name-style="western"><surname>Kholodov</surname><given-names>M.</given-names></name><etal>et al</etal>.</person-group> (<year>2001</year>) <article-title>dbSNP: the NCBI database of genetic variation</article-title>. <source>Nucleic Acids Res.</source>
<volume>29</volume>, <fpage>308</fpage>&#x02013;<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1093/nar/29.1.308</pub-id><pub-id pub-id-type="pmid">11125122</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heikkinen</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Greco</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Pelttari</surname><given-names>L.M.</given-names></name><etal>et al</etal>.</person-group> (<year>2011</year>) <article-title>Variants on the promoter region of PTEN affect breast cancer progression and patient survival</article-title>. <source>Breast Cancer Res.</source>
<volume>13</volume>, <fpage>R130</fpage>
<pub-id pub-id-type="doi">10.1186/bcr3076</pub-id><pub-id pub-id-type="pmid">22171747</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muranen</surname><given-names>T.A.</given-names></name>, <name name-style="western"><surname>Greco</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Fagerholm</surname><given-names>R.</given-names></name><etal>et al</etal>.</person-group> (<year>2011</year>) <article-title>Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications</article-title>. <source>Breast Cancer Res.</source>
<volume>13</volume>, <fpage>R90</fpage>
<pub-id pub-id-type="doi">10.1186/bcr3015</pub-id><pub-id pub-id-type="pmid">21542898</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leek</surname><given-names>J.T.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>W.E.</given-names></name>, <name name-style="western"><surname>Parker</surname><given-names>H.S.</given-names></name><etal>et al</etal>.</person-group> (<year>2012</year>) <article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title>. <source>Bioinformatics</source>
<volume>28</volume>, <fpage>882</fpage>&#x02013;<lpage>883</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/bts034</pub-id><pub-id pub-id-type="pmid">22257669</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Therneau</surname><given-names>T.M.</given-names></name> and <name name-style="western"><surname>Grambsch</surname><given-names>P.M.</given-names></name></person-group> (<year>2000</year>) <source>Modeling Survival Data: Extending the Cox Model</source>, <publisher-name>Springer&#x02010;Verlag</publisher-name>, <publisher-loc>New York</publisher-loc>, <comment>ISBN: 0-387-98784-3</comment></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Fagerholm</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kadalayil</surname><given-names>L.</given-names></name><etal>et al</etal>.</person-group> (<year>2018</year>) <article-title>Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer</article-title>. <source>Oncotarget</source>
<volume>9</volume>, <fpage>4249</fpage>&#x02013;<lpage>4257</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.22747</pub-id><pub-id pub-id-type="pmid">29423119</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bendl</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Musil</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>&#x00160;toura&#x0010d;</surname><given-names>J.</given-names></name><etal>et al</etal>.</person-group> (<year>2016</year>) <article-title>PredictSNP2: a unified platform for accurately evaluating SNP effects by exploiting the different characteristics of variants in distinct genomic regions</article-title>. <source>PLoS Comput. Biol.</source>
<volume>12</volume>, <fpage>e1004962</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pcbi.1004962</pub-id><pub-id pub-id-type="pmid">27224906</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ambrosini</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Bucher</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>) <article-title>SNP2TFBS - a database of regulatory SNPs affecting predicted transcription factor binding site affinity</article-title>. <source>Nucleic Acids Res.</source>
<volume>45</volume>, <fpage>D139</fpage>&#x02013;<lpage>D144</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw1064</pub-id><pub-id pub-id-type="pmid">27899579</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Pache</surname><given-names>L.</given-names></name><etal>et al</etal>.</person-group> (<year>2019</year>) <article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title>. <source>Nat. Commun.</source>
<volume>10</volume>, <fpage>1523</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id><pub-id pub-id-type="pmid">30944313</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warde-Farley</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Donaldson</surname><given-names>S.L.</given-names></name>, <name name-style="western"><surname>Comes</surname><given-names>O.</given-names></name><etal>et al</etal>.</person-group> (<year>2010</year>) <article-title>The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function</article-title>. <source>Nucleic Acids Res.</source>
<volume>38</volume>, <fpage>W214</fpage>&#x02013;<lpage>W220</lpage><pub-id pub-id-type="pmid">20576703</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foo</surname><given-names>L.C.</given-names></name> and <name name-style="western"><surname>Dougherty</surname><given-names>J.D.</given-names></name></person-group> (<year>2013</year>) <article-title>Aldh1L1 is expressed by postnatal neural stem cells in vivo</article-title>. <source>Glia</source>
<volume>61</volume>, <fpage>1533</fpage>&#x02013;<lpage>1541</lpage>
<pub-id pub-id-type="doi">10.1002/glia.22539</pub-id><pub-id pub-id-type="pmid">23836537</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahiya</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Sherman-Baust</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>T.L.</given-names></name><etal>et al</etal>.</person-group> (<year>2008</year>) <article-title>MicroRNA expression and identification of putative miRNA targets in ovarian cancer</article-title>. <source>PLoS ONE</source>
<volume>3</volume>, <fpage>e2436</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0002436</pub-id><pub-id pub-id-type="pmid">18560586</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nobukuni</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Mitsubuchi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Endo</surname><given-names>F.</given-names></name><etal>et al</etal>.</person-group> (<year>1990</year>) <article-title>Maple syrup urine disease. Complete primary structure of the E1 beta subunit of human branched chain alpha-ketoacid dehydrogenase complex deduced from the nucleotide sequence and a gene analysis of patients with this disease</article-title>. <source>J. Clin. Invest.</source>
<volume>86</volume>, <fpage>242</fpage>&#x02013;<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1172/JCI114690</pub-id><pub-id pub-id-type="pmid">2365818</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamakawa</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>D.Q.</given-names></name> and <name name-style="western"><surname>Korenberg</surname><given-names>J.R.</given-names></name></person-group> (<year>1996</year>) <article-title>A periodic tryptophan protein 2 gene homologue (PWP2H) in the candidate region of progressive myoclonus epilepsy on 21q22.3</article-title>. <source>Cytogenet. Cell Genet.</source>
<volume>74</volume>, <fpage>140</fpage>&#x02013;<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1159/000134402</pub-id><pub-id pub-id-type="pmid">8893822</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatakeyama</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>) <article-title>TRIM family proteins: roles in autophagy, immunity, and carcinogenesis</article-title>. <source>Trends Biochem. Sci.</source>
<volume>42</volume>, <fpage>297</fpage>&#x02013;<lpage>311</lpage>
<pub-id pub-id-type="doi">10.1016/j.tibs.2017.01.002</pub-id><pub-id pub-id-type="pmid">28118948</pub-id></mixed-citation></ref></ref-list></back></article>